Abstract 1415: The search for molecular biomarkers of relapse in early stage lung adenocarcinoma

Abstract

Abstract Background: Recurrence cannot be completely prevented by resection or chemotherapy. Molecular biomarkers reported in previous studies have the potential to predict the recurrence risk of lung adenocarcinoma (LUAD), but the results were controversial. Methods: We retrospectively analyzed the molecular characteristics of the 218 early-stage patients with lung adenocarcinoma based on 599 gene-panel target sequencing. All the patients received no neoadjuvant therapy and no EGFR-TKI treatment. The follow-up information on recurrence was complete. Univariate and multivariate analyses were performed using the Cox proportional hazard models to investigate whether the common alterations in EGFR and KRAS were prognostic factors for relapse-free survival(RFS). Results: Among all the enrolled patients, the mutation rates of EGFR and KRAS were 47.6% and 9.3%, respectively. EGFR mutation was not proved to be a prognostics signature of relapse for lung adenocarcinoma regardless univariate and multivariate analysis (univariate: HR, 1.11; 95%CI, 0.82-1.50, P = 0.49; multivariate: HR, 1.18; 95%CI, 0.86-1.64, P = 0.31). The univariate and multivariate analysis identified KRAS alteration as an independent prognostic factor for a shorter RFS (univariate: HR, 1.64; 95%CI, 0.75-2.43, P < 0.05; multivariate: HR, 1.66; 95%CI, 1.19-2.32, P <0.05). For patients in pathological stage I, the patients with KRAS alterations showed significant recurrent risk compared with wild-type patients (HR, 2.02; 95%CI, 1.38-2.96; P <0.0.01). Conclusion: KRAS alterations rather than EGFR alterations were prognostic biomarkers of relapse for early-stage lung adenocarcinoma, especially for patients in pathological stage I. Citation Format: Honggang Ke, Zhongying Jing. The search for molecular biomarkers of relapse in early stage lung adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1415.